iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) iBio (NASDAQ:IBIO) will host a corporate update call on March 17, 2026 at 4:00 p.m. ET to discuss expansion into pulmonary hypertension associated with HFpEF (PH-HFpEF) and its engineered selective bispecific antibody program.iBio expects to select an optimized bispecific development candidate in Q3 2026 before starting IND-enabling activities.

#IBIO iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

www.stocktitan.net/news/IBIO/i-bio-to-provi...

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss iBio (NASDAQ: IBIO) reported preclinical body composition data for IBIO-610 in obese non-human primates showing a 6.7% reduction in visceral fat and a 5.2% reduction in total fat mass after two once-every-eight-week doses, with a slight uptick in lean mass.iBio also reported an extended 33.2-day half-life in obese NHPs and a projected human half-life up to 100 days, supporting potential twice-yearly dosing; full dataset and additional biomarker analyses will be presented at scientific conferences in 2026.

#IBIO iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

www.stocktitan.net/news/IBIO/i-bio-reports-...

iBio Announces $26 Million Private Placement iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for a private placement

#IBIO iBio Announces $26 Million Private Placement

www.stocktitan.net/news/IBIO/i-bio-announce...

#IBIO helping feed the children in our discord post #GME ER

ALL THINGS GAMESTOP
ALL DECEMVER LONG
@
www.youtube.com/watch?v=z8Lx...

Most Searched, Wednesday December 10, 2025 – Crystal Equity Research

Most searched small-cap stocks, Wed Dec 10th - #POM #ENVB #DNN #NXDR #IBIO #PLUG #WRBY #TMC #RDW #SBET #PSIX #PARR #ONDS #MIGI #IRBT #HUN #FLWS #QUBT #BIAF #RR - More: crystalequityresearch.com/most-searche... - #smallcap

Here at the Symposium "Signalling and remodeling integrated by ROS, Ca+2 and autophagy from mosses to vascular plantas" within the XVII Reunión de Biología Vegetal 2025 at Valdivia Chile. We have the honor to have Jose Feijo (University of Maryland, USA) as keynote speaker. #UNAB #iBio #CBV

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update iBio (NASDAQ:IBIO) reported Q1 fiscal 2026 results and a corporate update on Nov 12, 2025. Key highlights include a closed $50.0M underwritten public offering of pre-funded warrants and common warrants with up to $100.0M potential gross proceeds if common warrants are fully exercised, and cash, cash equivalents and debt investments of $49.6M as of Sept 30, 2025, which the company says supports operations into the fourth quarter of fiscal 2027.iBio presented non-human primate data for IBIO-610 showing a predicted human half-life up to 100 days, consistent with dosing as infrequent as twice per year, and preclinical evidence of fat-selective, GLP-1–synergistic weight-loss and sustained weight maintenance.

#IBIO iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

www.stocktitan.net/news/IBIO/i-bio-reports-...

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance iBio (NASDAQ: IBIO) reported new preclinical data for IBIO-610, an Activin E antibody for fat-selective weight loss and maintenance. In obese non-human primates, IBIO-610 showed an extended half-life of 33.2 days. Using allometric scaling, iBio projects a predicted human half-life up to 100 days, potentially enabling dosing as infrequently as once every six months. Prior mouse data reportedly showed fat-selective, GLP-1-synergistic weight loss and prevention of weight regain after GLP-1 discontinuation. The NHP pharmacokinetic data and mechanistic preclinical results will be presented at ObesityWeek 2025.

#IBIO iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

www.stocktitan.net/news/IBIO/i-bio-unveils-...

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update iBio (NASDAQ:IBIO) reported its fiscal year 2025 results and corporate updates, highlighting significant progress in its cardiometabolic and obesity pipeline. The company's lead candidates include IBIO-610, an activin E-targeting antibody showing 26% fat mass reduction without lean mass loss, and IBIO-600, a long-acting anti-myostatin antibody demonstrating extended half-life and dose-dependent muscle growth.Financial highlights include revenue of $0.4M (up $0.2M YoY), R&D expenses of $8.3M (up $3.1M), and G&A expenses of $10.7M (down $1.0M). The company strengthened its position through a $50M public offering with potential for additional $50M from warrant exercises. iBio successfully transferred to Nasdaq trading and expanded its leadership team with industry veterans.

#IBIO iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/IBIO/i-bio-reports-...

iBio Announces Pricing of $50 Million Public Offering iBio (Nasdaq: IBIO) has announced the pricing of a $50 million public offering of pre-funded warrants and accompanying Series G warrants. The offering includes 71,540,000 pre-funded warrants to purchase common stock and Series G warrants to purchase 35,770,000 shares, along with Series H warrants.The combined offering price is set at $0.699 per unit, with Series G and H warrants having an exercise price of $0.70 per share. If all warrants are exercised, iBio could receive additional gross proceeds of approximately $50 million. The company plans to use the proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and fund working capital requirements. [ "Potential total gross proceeds of up to $100 million if all warrants are exercised", "Funds will advance key preclinical cardiometabolic programs IBIO-610 and IBIO-600", "Multiple tier-1 investment banks involved in the offering including Leerink Partners as lead bookrunner" ]

#IBIO iBio Announces Pricing of $50 Million Public Offering

www.stocktitan.net/news/IBIO/i-bio-announce...

Biotech iBio Unveils Strategic Public Offering to Accelerate Development of IBIO-610 and IBIO-600 Programs AI-driven antibody therapeutics company iBio commences public offering of pre-funded and series warrants to advance cardiometabolic programs IBIO-610 and IBIO-600. Leerink Partners leads offering.

#IBIO iBio Announces Proposed Public Offering

www.stocktitan.net/news/IBIO/i-bio-announce...

Trade Alerts, Wednesday August 13, 2025 – Crystal Equity Research

Small-cap stocks oversold with improving relative strength, Wed Aug 13th - #CYCA #MURA #LGVN #IBIO #HRTX #FNKO #FAT #ACXP #TIC #FVRR - More: crystalequityresearch.com/trade-alerts... - #smallcap

iBio and AstralBio Advance Novel Obesity Therapy with Promising Early Results iBio, Inc. (IBIO) is pushing deeper into the obesity treatment race with its partner AstralBio, unveiling compelling preclinical data for a new antibody-based t

#IBIO and AstralBio are making strides in the fight against obesity with early data showing promise for a novel therapeutic approach targeting key metabolic pathways.
prismmarketview.com/ibio-and-ast...

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results iBio (NASDAQ:IBIO) has announced promising preclinical results for its novel amylin receptor agonist antibody in obesity treatment. The engineered antibody demonstrated a significant 60% reduction in acute food intake in mouse models, comparable to the 67% reduction achieved by a clinically advanced DACRA peptide.This marks the third target from iBio's partnership with AstralBio, leveraging their AI-enabled antibody discovery platform to develop selective amylin receptor targeting treatments. The approach shows potential for both monotherapy and combination therapy with GLP-1 receptor agonists, with current amylin analogs achieving up to 22.7% weight loss in combination with semaglutide and 11.8% as monotherapy in clinical development.

#IBIO iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

www.stocktitan.net/news/IBIO/i-bio-and-astr...

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model iBio (NASDAQ: IBIO) has announced promising preclinical results for its first-in-class Activin E antibody in treating obesity. In a 4-week study with obese mice, the antibody achieved a 26% reduction in fat mass while preserving muscle mass. The treatment demonstrated significant reductions in various fat deposits: 31% in subcutaneous fat and 34-37% in visceral fat depots linked to cardiometabolic disease risk.When combined with a GLP-1 receptor agonist, the Activin E antibody showed remarkable synergy, achieving a 77% reduction in total fat mass and total weight loss of 35.3% - surpassing GLP-1 alone by 7.5%. Unlike current obesity drugs that may reduce muscle mass, iBio's approach focuses on fat-specific weight loss, potentially offering a more effective solution for obesity treatment while maintaining physical function and healthy metabolism.

#IBIO iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

www.stocktitan.net/news/IBIO/i-bio-s-first-...

iBio Reports Strong Pipeline Data and Nasdaq Uplisting as Q3 R&D Investment Doubles iBio advances IBIO-600 with promising primate data, secures Activin E antibody license, and raises $6.2M post-quarter. See full pipeline and financial details.

#IBIO iBio Reports Fiscal Third Quarter 2025 Financial Results

www.stocktitan.net/news/IBIO/i-bio-reports-...

iBio Raises $6.2 Million Through Warrant Inducement Transaction iBio, an AI-driven innovator of precision antibody therapies, has secured $6.2 million through a warrant inducement transaction with institutional investors. The deal involves existing warrant holders agreeing to purchase 5,626,685 shares of common stock at a reduced price of $1.11 per share. As part of the agreement, investors received new warrants to purchase up to 11,253,370 shares at $0.86 per share, with a five-year expiration period. The transaction is expected to close around April 30, 2025, with Chardan serving as the exclusive financial advisor. The company plans to use the net proceeds for working capital and general corporate purposes. The new securities are being offered through a private placement and will require registration with the SEC before they can be sold in the United States.

#IBIO iBio Raises $6.2 Million Through Warrant Inducement Transaction

www.stocktitan.net/news/IBIO/i-bio-raises-6...

Monday’s Movers, 3 Fresh Plays **Thursday’s Runners:** We got things right back on track with the options trading ideas we offered up in **our premarket report** for Monday’s session. We went fully bearish on all our ideas, and with some help from another terrible session for the markets, we had good opportunities across the board. Those targets were the **NVDA Weekly $100-98 Puts** , the **SPY 04/21 $523-521 Puts** , and the **TSLA Weekly $235-232.50 Puts,** and these were their best moves of the day: **NVDA Weekly $100-98 Puts $100: **3.25-6.05 (+86%) **$99:** 2.85-5.30 (+86%) **$98:** 2.45-4.65 (+90%) _____ **SPY 04/21 $523-521 Puts** **$523:** 3.50-14.39 (+311%) **$522:** 2.97-13.37 (+350%) **$521:** 2.57-12.52 (+387%) _____ **TSLA Weekly $235-232.50 Puts** **$235:** 13.96-19.21 (+38%) **$232.50:** 12.69-17.64 (+39%)** ** * * * **Fresh Options Ideas:** **DHR Weekly $192.50-195 Calls GE Weekly $182.50-185 Calls VZ Weekly $41.50-40 Puts ** _*Trading options contracts on their day of expiration should only be attempted by experienced traders _ * * * **Upexi, Inc. (NASDAQ:UPXI) – Recap: ** We also saw a really good move out of UPXI yesterday after including it in our extended watchlist for the day. It ran from 9.02-22.00 for an overall rise of 144% * * * **Extended Watchlist: OCEA, WNW, GELS, TIVC, IBIO, MLGO, HOLO, WHLR**

Monday’s Movers, 3 Fresh Plays Thursday’s Runners: We got things right back on track with the...

bluehorseshoestocks.com/mondays-movers-3-fresh-p...

#Daily #Report #DHR #GE #GELS #HOLO #IBIO #MLGO #NVDA #OCEA #SPY

Result Details

Revolutionary AI-Discovered Obesity Drug: iBio Licenses First-Ever Activin E Antibody in $28M Deal Novel antibody shows fat-selective weight loss in preclinical studies. $28M milestone deal expands iBio's cardiometabolic pipeline. Discover the AI-powered breakthrough.

#IBIO iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

www.stocktitan.net/news/IBIO/i-bio-expands-...

Can iBio's Nasdaq Move Transform Its Market Presence? Key Details Revealed iBio transitions to Nasdaq Capital Market, targeting improved liquidity and institutional investor exposure while maintaining IBIO ticker symbol.

#IBIO iBio to Begin Trading on the Nasdaq Stock Exchange

www.stocktitan.net/news/IBIO/i-bio-to-begin...

IBIO's Strategic Pivot: AI-Powered Antibody Discovery Shows Promise Despite Q2 Losses iBio reports $0.2M revenue, advances novel antibody programs through AI platform, while strengthening board and securing funding from insiders.

#IBIO iBio Reports Fiscal Second Quarter 2025 Financial Results

www.stocktitan.net/news/IBIO/i-bio-reports-...

Breaking News: ( NYSE: #IBIO ) iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

iBio and AstralBio Breakthrough: Novel Antibody Targets Obesity and Diabetes Through Activin E Inhibition Groundbreaking collaboration develops first functional antibody against Activin E, showing promise for cardiometabolic disorders with complete signaling blockade in human adipocytes.

#IBIO iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

www.stocktitan.net/news/IBIO/i-bio-discover...

iBio Acquires Promising Anti-Myostatin Antibody for Obesity Treatment in $28.75M Deal iBio expands cardiometabolic portfolio with IBIO-600, showing 10x higher binding affinity in preclinical studies. Deal includes $750K upfront plus milestone payments.

#IBIO iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

www.stocktitan.net/news/IBIO/i-bio-expands-...

#IBIO iBio Strengthens Board with Appointment of Two New Independent Directors

www.stocktitan.net/news/IBIO/i-bio-strength...

Cellular respiration- classic. #FreshmanBio #IBio #Teacher

503 Service Unavailable

#iBio founder R Vale + speakers @dacolon @jessicapolka & H Varmus organize #asapbio to discuss preprints in biology http://asapbio.org/